|
Astrocytomas
|
|
|
|
Stuart A.
Grossman, Jane B. Alavi,
Jeffrey G. Supko, Kathryn A. Carson, Regina Priet, F. Andrew Dorr,
John S. Grundy, and Jon T. Holmlund
Efficacy and toxicity of the antisense
oligonucleotide aprinocarsen directed against protein kinase C-α
delivered as a 21-day continuous intravenous infusion in patients with
recurrent high-grade astrocytomas
Neuro-Oncology, Volume
7, Number 1, Pages 32 -- 40, January 2005. (Clinical Study,
Abstract+)
|
|
|
|
|
Atypical
Teratoid/Rhabdoid
T.
|
|
|
D'cunja
J, Shalaby T, Rivera P, von Buren A, Patti R, Heppner FL, Arcaro A, Rorke-Adams
LB, Phillips PC, Grotzer MA.
Antisense treatment of IGF-IR induces apoptosis and enhances
chemosensitivity in central nervous system atypical teratoid/rhabdoid
tumours cells.
Eur J
Cancer. 2007 Apr 17; [Epub ahead of print]
PMID: 17446062 [PubMed - as supplied by publisher]
|
|
|
|
|
Gliomas
|
|
|
U. Bogdahn, P. Hau, A.
Brawanski, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichler, M. Kunst, G.
Stauder, K.-H. Schlingensiepen
Specific therapy for high-grade glioma by
convection-enhanced delivery of the TGF-β2 specific antisense
oligonucleotide AP 12009
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1514 (Clinical
Study)
|
|
Ulrich Bogdahn, Peter Hau, Alexander Brawanski, Juergen
Schlaier, Maximilian Mehdorn, Arya Nabavi, Gabriele Wurm, Josef Pichler,
Mechthild Kunst, Michael Goldbrunner, Gerhard Stauder, Gerhard Stauder,
Karl-Hermann Schlingensiepen
Tgf-beta2 suppression by the antisense oligonucleotide ap 12009
as therapy for high-grade glioma: Safety and efficacy results of phase i/ii
clinical studies
Proceedings of the AACR, Volume 45, March 2004, Abstract
Number: 5239. (Clinical Study)
|
|
Matsuno A, Katayama H, Murakami M, Nagashima
T
In vivo growth suppression of rat C6 glioma transplanted
in rat brain using antisense oligonucleotide for microtubule-associated
protein 1A messenger ribonucleic acid
Br
J Neurosurg. 2004 Aug;18(4):343-6. (Laboratory
Investigation, Abstract)
|
|
G.
M. Stauder, P. Hau, U. Bogdahn, A. Steinbrecher, A. Brawanski, J.
Schlaier, G. Wurm, J. Pichler, M. Kunst, K.-H. Schlingensiepen
A
TGF-beta2 specific antisense oligonucleotide (AP12009) as continuous
intratumoral treatment of recurrent high-grade glioma patients: A clinical
phase I/II extension study
39th
ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No.
436
(Clinical Study)
|
|
